Unicycive Therapeutics Inc Financials
Financial Health Signals
Unicycive Therapeutics Inc passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass.
For every $1 of reported earnings, Unicycive Therapeutics Inc generates $0.78 in operating cash flow (-$28.6M OCF vs -$36.7M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Unicycive Therapeutics Inc earns $-452.4 in operating income for every $1 of interest expense (-$32.1M vs $71K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
This page shows Unicycive Therapeutics Inc (UNCY) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Unicycive Therapeutics Inc's EBITDA was -$32.1M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 54.6% from the prior year.
Unicycive Therapeutics Inc generated -$28.6M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 56.6% from the prior year.
Unicycive Therapeutics Inc reported -$36.7M in net income in fiscal year 2024. This represents a decrease of 20.2% from the prior year.
Unicycive Therapeutics Inc earned $-0.56 per diluted share (EPS) in fiscal year 2024. This represents an increase of 56.3% from the prior year.
Unicycive Therapeutics Inc held $26.1M in cash against $0 in long-term debt as of fiscal year 2024.
Unicycive Therapeutics Inc had 11M shares outstanding in fiscal year 2024. This represents a decrease of 67.2% from the prior year.
Unicycive Therapeutics Inc invested $20.0M in research and development in fiscal year 2024. This represents an increase of 55.1% from the prior year.
Unicycive Therapeutics Inc invested $72K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 500.0% from the prior year.
UNCY Income Statement
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q1'23 | Q4'22 | Q3'22 | Q4'21 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | $675K | N/A | $951K | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $3.0M-2.7% | $3.0M | N/A | $3.4M+11.3% | $3.0M | N/A | $4.8M | N/A |
| SG&A Expenses | $4.4M+36.6% | $3.2M | N/A | $479K+672.6% | $62K | N/A | $163K | N/A |
| Operating Income | -$7.3M-17.5% | -$6.3M | N/A | -$5.9M-41.3% | -$4.2M | N/A | -$5.6M | N/A |
| Interest Expense | $15K0.0% | $15K | N/A | $18K+50.0% | $12K | N/A | $3K | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$6.0M-46.8% | -$4.1M | N/A | -$4.3M+70.3% | -$14.6M | N/A | -$5.6M | N/A |
| EPS (Diluted) | $-0.33+28.3% | $-0.46 | N/A | $-0.13+86.6% | $-0.97 | N/A | $-0.37 | N/A |
UNCY Balance Sheet
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q1'23 | Q4'22 | Q3'22 | Q4'21 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $50.6M+59.8% | $31.7M+123.2% | $14.2M-27.0% | $19.4M-28.5% | $27.2M+865.3% | $2.8M-72.3% | $10.2M-45.7% | $18.7M |
| Current Assets | $50.3M+62.5% | $30.9M+131.0% | $13.4M-27.8% | $18.6M-29.1% | $26.2M+890.3% | $2.6M-73.5% | $10.0M-45.9% | $18.4M |
| Cash & Equivalents | $42.7M+63.3% | $26.1M+169.5% | $9.7M-32.4% | $14.3M-41.0% | $24.3M+5247.7% | $455K-93.5% | $7.0M-57.7% | $16.6M |
| Inventory | N/A | N/A | N/A | $3.1M+68.0% | $1.9M-15.4% | $2.2M-25.8% | $3.0M+61.1% | $1.8M |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $13.1M-45.8% | $24.2M+34.6% | $18.0M+12.4% | $16.0M-62.1% | $42.3M+1187.6% | $3.3M-40.8% | $5.6M+145.6% | $2.3M |
| Current Liabilities | $13.1M-45.6% | $24.1M+37.6% | $17.5M+13.4% | $15.5M-3.2% | $16.0M+386.3% | $3.3M-40.5% | $5.5M+162.3% | $2.1M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $37.5M+404.4% | $7.4M+295.1% | -$3.8M-210.9% | $3.4M+122.8% | -$15.1M-3136.5% | -$466K-110.1% | $4.6M-71.9% | $16.5M |
| Retained Earnings | -$113.2M-11.7% | -$101.3M-56.9% | -$64.5M-13.7% | -$56.7M-16.8% | -$48.6M-42.9% | -$34.0M-18.6% | -$28.7M-79.9% | -$15.9M |
UNCY Cash Flow Statement
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q1'23 | Q4'22 | Q3'22 | Q4'21 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$6.0M+8.9% | -$6.5M-47.5% | -$4.4M-0.4% | -$4.4M-12.8% | -$3.9M+35.6% | -$6.1M-70.8% | -$3.6M-154.0% | -$1.4M |
| Capital Expenditures | $2K-90.9% | $22K | $0 | $0 | N/A | $0 | $0 | N/A |
| Free Cash Flow | -$6.0M+9.2% | -$6.6M-48.0% | -$4.4M-0.4% | -$4.4M | N/A | -$6.1M-70.8% | -$3.6M | N/A |
| Investing Cash Flow | -$2K+90.9% | -$22K | $0 | $0 | N/A | $0 | $0 | N/A |
| Financing Cash Flow | $26.3M+7114.2% | $365K+278.0% | -$205K-302.0% | -$51K-100.2% | $27.8M | N/A | N/A | $0 |
| Dividends Paid | N/A | $0 | $0-100.0% | $100K-50.0% | $200K | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
UNCY Financial Ratios
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q1'23 | Q4'22 | Q3'22 | Q4'21 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | -622.5% | N/A | -584.0% | N/A |
| Net Margin | N/A | N/A | N/A | N/A | -2159.3% | N/A | -584.3% | N/A |
| Return on Equity | 5.1% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -11.9%-1.3pp | -10.6% | N/A | -22.3%+31.3pp | -53.6% | N/A | -54.6% | N/A |
| Current Ratio | 3.83+2.5 | 1.28+0.5 | 0.76-0.4 | 1.20-0.4 | 1.64+0.8 | 0.81-1.0 | 1.80-6.9 | 8.75 |
| Debt-to-Equity | 0.35-2.9 | 3.26+8.0 | -4.73-9.4 | 4.66+7.5 | -2.80+4.2 | -7.05-8.2 | 1.20+1.1 | 0.14 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | -374.7% | N/A |
Similar Companies
Frequently Asked Questions
Is Unicycive Therapeutics Inc profitable?
No, Unicycive Therapeutics Inc (UNCY) reported a net income of -$36.7M in fiscal year 2024.
What is Unicycive Therapeutics Inc's earnings per share (EPS)?
Unicycive Therapeutics Inc (UNCY) reported diluted earnings per share of $-0.56 for fiscal year 2024. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Unicycive Therapeutics Inc's EBITDA?
Unicycive Therapeutics Inc (UNCY) had EBITDA of -$32.1M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Unicycive Therapeutics Inc's free cash flow?
Unicycive Therapeutics Inc (UNCY) generated -$28.6M in free cash flow during fiscal year 2024. This represents a -56.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Unicycive Therapeutics Inc's operating cash flow?
Unicycive Therapeutics Inc (UNCY) generated -$28.6M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Unicycive Therapeutics Inc's total assets?
Unicycive Therapeutics Inc (UNCY) had $31.7M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Unicycive Therapeutics Inc's capital expenditures?
Unicycive Therapeutics Inc (UNCY) invested $72K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Unicycive Therapeutics Inc spend on research and development?
Unicycive Therapeutics Inc (UNCY) invested $20.0M in research and development during fiscal year 2024.
How many shares does Unicycive Therapeutics Inc have outstanding?
Unicycive Therapeutics Inc (UNCY) had 11M shares outstanding as of fiscal year 2024.
What is Unicycive Therapeutics Inc's current ratio?
Unicycive Therapeutics Inc (UNCY) had a current ratio of 1.28 as of fiscal year 2024, which is considered adequate.
What is Unicycive Therapeutics Inc's debt-to-equity ratio?
Unicycive Therapeutics Inc (UNCY) had a debt-to-equity ratio of 3.26 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Unicycive Therapeutics Inc's return on assets (ROA)?
Unicycive Therapeutics Inc (UNCY) had a return on assets of -116.0% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Unicycive Therapeutics Inc's cash runway?
Based on fiscal year 2024 data, Unicycive Therapeutics Inc (UNCY) had $26.1M in cash against an annual operating cash burn of $28.6M. This gives an estimated cash runway of approximately 11 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Unicycive Therapeutics Inc's Piotroski F-Score?
Unicycive Therapeutics Inc (UNCY) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Unicycive Therapeutics Inc's earnings high quality?
Unicycive Therapeutics Inc (UNCY) has an earnings quality ratio of 0.78x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Unicycive Therapeutics Inc cover its interest payments?
Unicycive Therapeutics Inc (UNCY) has an interest coverage ratio of -452.4x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.